Cervical Dysplasia Market By Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Cervical Dysplasia Market
Cervical Dysplasia Market: By Type (low-grade SIL, or LSIL (Squamous Intraepithelial Lesion), high-grade SIL, or HSIL, Cancer Bound SIL, Atypical glandular cells (AGUS)) Strategic Analysis(Value Chain, Pricing Analysis, Others) & By Geography-Forecast (2016-2021)
Report Code : HCR 0200
Updated Date: 26 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Cervical Dysplasia – Market Overview
2. Executive Summary
3. Cervical Dysplasia Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Cervical Dysplasia – Market Forces
   4.1. Drivers
      4.1.1. Globally increasing instances of STD’s and population with STD’s
   4.2. Restraints
      4.2.1. Environment impact & stringent regulations
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Cervical Dysplasia Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Cervical Dysplasia Market By Type
   6.1. low-grade SIL, or LSIL (Squamous Intraepithelial Lesion)
   6.2. high-grade SIL, or HSIL
   6.3. Cancer Bound SIL
   6.4. Atypical glandular cells (AGUS)
7. Cervical Dysplasia Market By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Cervical Dysplasia – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles
   9.1. Helix BioPharma Corp.  
      9.1.1. Introduction
      9.1.2. Financials
      9.1.3. Key Insights
      9.1.4. Key Strategy
      9.1.5. Product Portfolio
      9.1.6. SWOT Analysis
   9.2. PDS Biotechnology Corporation  
      9.2.1. Introduction
      9.2.2. Financials
      9.2.3. Key Insights
      9.2.4. Key Strategy
      9.2.5. Product Portfolio
      9.2.6. SWOT Analysis
   9.3. GlaxoSmithKline plc         
      9.3.1. Introduction
      9.3.2. Financials
      9.3.3. Key Insights
      9.3.4. Key Strategy
      9.3.5. Product Portfolio
      9.3.6. SWOT Analysis
   9.4. Inovio Biomedical Corporation
      9.4.1. Introduction
      9.4.2. Financials
      9.4.3. Key Insights
      9.4.4. Key Strategy
      9.4.5. Product Portfolio
      9.4.6. SWOT Analysis
   9.5. Photocure ASA      
      9.5.1. Introduction
      9.5.2. Financials
      9.5.3. Key Insights
      9.5.4. Key Strategy
      9.5.5. Product Portfolio
      9.5.6. SWOT Analysis
   9.6. AnGes MG, Inc.  
      9.6.1. Introduction
      9.6.2. Financials
      9.6.3. Key Insights
      9.6.4. Key Strategy
      9.6.5. Product Portfolio
      9.6.6. SWOT Analysis
   9.7. Advaxis, Inc.  
      9.7.1. Introduction
      9.7.2. Financials
      9.7.3. Key Insights
      9.7.4. Key Strategy
      9.7.5. Product Portfolio
      9.7.6. SWOT Analysis
   9.8. Vaccibody AS     
      9.8.1. Introduction
      9.8.2. Financials
      9.8.3. Key Insights
      9.8.4. Key Strategy
      9.8.5. Product Portfolio
      9.8.6. SWOT Analysis
   9.9. Eisai, Inc. 
      9.9.1. Introduction
      9.9.2. Financials
      9.9.3. Key Insights
      9.9.4. Key Strategy
      9.9.5. Product Portfolio
      9.9.6. SWOT Analysis
   9.10. CEL-SCI Corporation     
      9.10.1. Introduction
      9.10.2. Financials
      9.10.3. Key Insights
      9.10.4. Key Strategy
      9.10.5. Product Portfolio
      9.10.6. SWOT Analysis
*More than 10 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix

   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Expert Insights
Cervical dysplasia is a precancerous medical condition generally found in women under age 30. Cervical dysplasia results in abnormal cell growth which occurs on the surface lining of the cervix or endocervical canal, the opening between the uterus and the vagina and sometimes is also called cervical intraepithelial neoplasia (CIN). Cervical dysplasia is strongly associated with sexually transmitted human papillomavirus (HPV) infection, and though it is generally found in women under the age of 30, it can develop at any age.

This report identifies the cervical dysplasia market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape and other key aspects with respect to cervical dysplasia market.

Cervical Dysplasia Market

Globally North America dominated the market for cervical dysplasia in 2015 followed by Europe as second largest regional market. Major factor behind dominance of these two regions in cervical dysplasia market place are estimated to be high awareness levels among people about the disease and its treatments as well as well-established healthcare infrastructure with advanced treatments in these regions. Asia- Pacific is expected to witness strong growth in the cervical dysplasia market during the period of study due to increasing reported instances of the disease coupled with increasing awareness and rapidly developing healthcare infrastructure in the region especially in major developing economies like India and China.

This report on cervical dysplasia also covers different type cervical dysplasia, and market size in various geographical regions.
  • The report covers major types of cervical dysplasia, some of the major cervical dysplasia types are as follows: low-grade SIL, or LSIL (Squamous Intraepithelial Lesion), high-grade SIL, or HSIL, Cancer Bound SIL and Atypical glandular cells (AGUS)
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for cervical dysplasia in each of the region.

Sample Companies Profiled in this Report are: 
  • Helix BioPharma Corp.  
  • PDS Biotechnology Corporation  
  • GlaxoSmithKline plc         
  • Inovio Biomedical Corporation
  • Photocure ASA
  • 10+
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports